Status:
UNKNOWN
Hydroxychloroquine in Systemic Lupus Erythematosus
Lead Sponsor:
McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborating Sponsors:
Laval University
University of British Columbia
Conditions:
Systemic Lupus Erythematosus
Eligibility:
All Genders
18+ years
Brief Summary
A Systemic lupus erythematosus, SLE is disease in which immune system is over-active causing inflammation in joints skin or any organ system. There are many areas where better approaches in SLE could ...
Detailed Description
B OBJECTIVES B1 To evaluate in SLE patients who lower but do not discontinue HCQ factors associated with flare (significant increase in disease activity, augmentation of therapy or hospitalization for...
Eligibility Criteria
Inclusion
- Must be 18 years of age or over
- Must be diagnosed with Systemic Lupus Erythematosus (SLE)
- Must be exposed to hydroxychloroquine
- Must be enrolled at participating sites
Exclusion
- Under 18 years of age
- Not diagnosed with SLE
- Not exposed to hydroxychloroquine
- Not enrolled at participating sites
Key Trial Info
Start Date :
May 9 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2025
Estimated Enrollment :
3700 Patients enrolled
Trial Details
Trial ID
NCT03802188
Start Date
May 9 2018
End Date
March 31 2025
Last Update
January 14 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Institute of the McGill University Health Centre
Montreal, Quebec, Canada, H3H 2R9